[132] Rethinking Medication Adherence
Vignette: An 83 year old faces conflict between her own preference for a simpler medication regime and a specialist who emphasizes that she will “need” to take her 8 drugs (14 doses/day) “for the rest of her life.” She takes an NSAID regularly because it helps with pain, but not the bisphosphonate “pill for my bones”. She finds it hard to swallow and doubts that the small chance of preventing a … [Read more...]
[131] Tramadol: Where do we go from here?
Tramadol was marketed as an opioid analgesic in Germany in 1977, but not licenced in Canada until 2005. Health Canada has announced that it will add tramadol to Schedule I of the Controlled Drugs and Substances Act and to the Narcotic Control Regulations in March 2022.1 In Africa and the Middle East, abuse of tramadol is a recognized international crisis, in part because of its marketing as a … [Read more...]
[Sep 15] Best Evidence Webinar: VTE prophylaxis in medical patients: is it worth it?
Dr. Aaron M Tejani is a researcher/educator/pharmacist with the Therapeutics Initiative (co-chair of the Education Working Group), a clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), and Medication use evaluation pharmacist with Lower Mainland Pharmacy Services (Vancouver, BC). He completed his BSc(Pharm) at UBC (Vancouver) and Doctor of … [Read more...]
Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study
Colin R. Dormuth, Anat Fisher, Marie Hudson, Peter C. Austin, Pierre Ernst, Lauren Bresee, Dan Chateau, Hala Tamim, J. Michael Paterson, Jean Philippe Lafrance, Regina M. Taylor-Gjevre, Robert W. Platt, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: … [Read more...]
[130] Evidence for statins in people over 70
Therapeutics Letters 48, 49 and 77 summarized the effects of statins in secondary and primary prevention populations studied in randomized controlled trials (RCTs).1,2,3 This best available evidence comes from RCTs that enrolled mostly men aged 50-70. There is much less evidence for use of statins after age 70. Yet in 2020 47% of men and 33% of women over 70 in British Columbia took a statin. … [Read more...]
Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study
Lix LM, Sobhan S, St-Jean A, Daigle J-M, Fisher A, et al. Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study. BMC Health Serv Res 21, 758 (2021). https://doi.org/10.1186/s12913-021-06762-0 Abstract Background Cardiovascular death is a common outcome in population-based studies about new healthcare … [Read more...]
[Aug 25] TI Methods Speaker Series: Do we need journal peer review? Changes between 121 epidemiology preprints and their subsequent journal publications
TI Methods Speaker Series The TI Methods Speaker Series are offered free of charge and everyone is welcome. The event is held at noon on the last Wednesday of each month and used to take place in Rudy North Lecture Theatre (CBH 101) in the Centre for Brain Health, UBC Point Grey Campus. During the COVID-19 pandemic, while physical distancing measures are in effect, the TI Methods Speaker Series … [Read more...]
[Jul 28] TI Methods Speaker Series: QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies
TI Methods Speaker Series The TI Methods Speaker Series are offered free of charge and everyone is welcome. The event is held at noon on the last Wednesday of each month and used to take place in Rudy North Lecture Theatre (CBH 101) in the Centre for Brain Health, UBC Point Grey Campus. During the COVID-19 pandemic, while physical distancing measures are in effect, the TI Methods Speaker Series … [Read more...]
[129] Mirtazapine: Update on efficacy, safety, dose response
Soon after mirtazapine was licensed in Canada, a 2002 Therapeutics Letter concluded that it has “no proven efficacy or safety advantage over other antidepressant therapies”.1 Mirtazapine was approved for symptomatic relief of depressive illness and marketed as an alternative to selective serotonin reuptake inhibitors (SSRIs) which had dominated the antidepressant market from the late 1980s.2 As … [Read more...]
[Jul 14] Shedding light on the risks of anticholinergic drugs: NEW information on risk of dementia and harm in the frail elderly
Did you know that 8% of the top 200 drugs prescribed in BC are anticholinergic drugs? Dr. Aaron M Tejani is a researcher with the Therapeutics Initiative (co-chair of the Education Working Group and the Drug Assessment Working Group), a clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), and Medication use evaluation pharmacist with Lower … [Read more...]
- 1
- 2
- 3
- …
- 33
- Next Page »
